Profile data is unavailable for this security.
About the company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
- Revenue in USD (TTM)0.00
- Net income in USD-35.76m
- Incorporated2007
- Employees11.00
- LocationForte Biosciences Inc3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS 75247United StatesUSA
- Phone+1 (310) 618-6994
- Fax+1 (302) 655-5049
- Websitehttps://www.fortebiorx.com/home/default.aspx
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kintara Therapeutics Inc | 0.00 | -9.51m | 9.63m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 9.67m | 20.00 | -- | -- | -- | 1.76 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.35k | -13.93m | 9.67m | 12.00 | -- | 0.9028 | -- | 630.04 | -0.8448 | -0.8448 | 0.0008 | 0.3597 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -1.24m | 9.75m | 22.00 | -- | 0.8041 | -- | 139.29 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.57m | 9.89m | 85.00 | -- | 0.4174 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Jaguar Health Inc | 10.19m | -35.67m | 9.89m | 49.00 | -- | 0.4954 | -- | 0.9709 | -41.34 | -41.34 | 6.62 | 2.48 | 0.1793 | 0.231 | 7.56 | 207,857.10 | -63.73 | -95.29 | -110.34 | -163.54 | 79.79 | 67.28 | -355.51 | -522.28 | 1.60 | -3.45 | 0.6333 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Virax Biolabs Group Ltd | 156.42k | -6.73m | 9.94m | 17.00 | -- | 1.17 | -- | 63.55 | -3.35 | -3.35 | 0.078 | 2.09 | 0.0205 | 3.51 | -- | 9,201.18 | -88.11 | -- | -91.88 | -- | 32.34 | -- | -4,308.35 | -- | 25.58 | -227.16 | 0.0418 | -- | 1,727.34 | -- | -23.38 | -- | -- | -- |
| Avalo Therapeutics Inc | 807.00k | -36.22m | 10.05m | 19.00 | -- | -- | -- | 12.46 | -63.82 | -63.82 | 0.3347 | -2.08 | 0.0122 | -- | 20.96 | 42,473.68 | -54.66 | -99.64 | -529.15 | -154.42 | 64.19 | 84.69 | -4,488.60 | -613.58 | -- | -- | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 10.29m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Forte Biosciences Inc | 0.00 | -35.76m | 10.34m | 11.00 | -- | 0.6085 | -- | -- | -22.03 | -22.03 | 0.00 | 11.64 | 0.00 | -- | -- | 0.00 | -124.89 | -72.06 | -170.91 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Enzon Pharmaceuticals Inc | 26.00k | 314.00k | 10.45m | 0.00 | 33.29 | 3.44 | -- | 401.90 | 0.0042 | 0.0042 | 0.0004 | 0.6277 | 0.0006 | -- | -- | -- | 3.39 | -0.8654 | 3.42 | -0.8851 | -- | -- | 6,111.54 | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| Kineta Inc | 0.00 | -20.88m | 10.54m | 11.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.6638 | 0.00 | -- | -- | 0.00 | -220.35 | -66.16 | -- | -86.61 | -- | -- | -- | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Yubo International Biotech Ltd | 454.29k | -1.42m | 10.54m | 18.00 | -- | -- | -- | 23.21 | -0.0118 | -0.0118 | 0.0038 | -0.0211 | 0.2462 | 0.5986 | 3.49 | 25,238.33 | -82.33 | -- | -- | -- | 80.30 | -- | -334.36 | -- | 0.1707 | -4,795.69 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 10.63m | 35.00 | -- | 0.5297 | -- | 1,062.70 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 10.87m | 12.00 | -- | 0.3285 | 4.03 | 0.6787 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Forte Biosciences Inc's reporting currency: US Dollar USD
53.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tybourne Capital Management (HK) Ltd.as of 30 Jun 2024 | 144.98k | 9.93% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 130.61k | 8.95% |
| BVF Partners LPas of 30 Jun 2024 | 119.28k | 8.17% |
| Cable Car Capital LLCas of 30 Jun 2024 | 81.28k | 5.57% |
| Fred Alger Management LLCas of 30 Jun 2024 | 73.56k | 5.04% |
| Farallon Capital Management LLCas of 30 Jun 2024 | 72.42k | 4.96% |
| BML Capital Management LLCas of 30 Jun 2024 | 70.47k | 4.83% |
| Camac Partners LLCas of 14 Jun 2024 | 51.09k | 3.50% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 25.69k | 1.76% |
| Geode Capital Management LLCas of 30 Jun 2024 | 13.85k | 0.95% |
More ▼
Data from 30 Jun 2024 - 08 Aug 2024Source: FactSet Research Systems Inc.
